Alpa Laboratories Reports Q3FY26 Results with Revenue Growth of 13.5% YoY
Alpa Laboratories Limited reported Q3FY26 results with revenue growth of 13.5% to Rs 2,967.12 lacs, but net profit declined 78.9% to Rs 187.48 lacs. Nine-month revenue grew 2.6% to Rs 7,441.40 lacs while profit fell 36.5% to Rs 1,375.20 lacs. The pharmaceutical company operates in drugs and chemicals segment.
*this image is generated using AI for illustrative purposes only.
Alpa Laboratories Limited announced its unaudited financial results for the quarter ended December 31, 2025, showing mixed performance with revenue growth but declining profitability compared to the previous year.
Financial Performance Overview
The pharmaceutical company reported revenue from operations of Rs 2,967.12 lacs for Q3FY26, representing a growth of 13.5% from Rs 2,615.02 lacs in the corresponding quarter of FY25. However, net profit declined significantly to Rs 187.48 lacs from Rs 889.30 lacs in Q3FY25, marking a decrease of 78.9%.
| Metric | Q3FY26 | Q3FY25 | Change (%) |
|---|---|---|---|
| Revenue from Operations | Rs 2,967.12 lacs | Rs 2,615.02 lacs | +13.5% |
| Total Income | Rs 2,993.17 lacs | Rs 3,495.19 lacs | -14.4% |
| Net Profit | Rs 187.48 lacs | Rs 889.30 lacs | -78.9% |
| Earnings Per Share | Rs 0.89 | Rs 4.24 | -79.0% |
Nine-Month Performance
For the nine months ended December 31, 2025, Alpa Laboratories achieved revenue from operations of Rs 7,441.40 lacs compared to Rs 7,253.26 lacs in the corresponding period of the previous year, showing growth of 2.6%. Net profit for the nine-month period stood at Rs 1,375.20 lacs versus Rs 2,166.42 lacs in the previous year.
| Parameter | 9M FY26 | 9M FY25 | Change (%) |
|---|---|---|---|
| Revenue from Operations | Rs 7,441.40 lacs | Rs 7,253.26 lacs | +2.6% |
| Net Profit | Rs 1,375.20 lacs | Rs 2,166.42 lacs | -36.5% |
| Earnings Per Share | Rs 6.54 | Rs 10.31 | -36.6% |
Cost Structure Analysis
The company's cost structure showed significant changes during the quarter. Cost of materials consumed increased substantially to Rs 1,816.08 lacs in Q3FY26 from Rs 1,273.98 lacs in Q3FY25. Employee benefit expenses rose to Rs 371.79 lacs from Rs 336.11 lacs year-over-year. Other income declined sharply to Rs 26.05 lacs from Rs 880.17 lacs in the previous year quarter.
Consolidated Results
On a consolidated basis, which includes subsidiary Norfolk Mercantile Private Limited, the company reported revenue from operations of Rs 2,904.58 lacs for Q3FY26. Consolidated net profit was Rs 190.29 lacs compared to Rs 890.18 lacs in Q3FY25. The subsidiary contributed minimal revenue but reported a net loss of Rs 3.42 lacs for both the quarter and nine-month periods.
Corporate Information
Alpa Laboratories Limited operates in the single segment of drugs and chemicals. The company maintains its registered office at 33/2, A.B. Road, Pigdamber-453446, District Indore, Madhya Pradesh. The Board of Directors approved these unaudited standalone and consolidated financial results in a meeting held on February 11, 2026, with limited review reports from statutory auditors C.H. Padliya & Co.
Historical Stock Returns for Alpa Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.60% | +6.12% | -2.96% | -24.17% | -35.30% | +91.83% |
20
